Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06629363
Recruiting Observational

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

NCT06629363 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de PAU
Phase
Observational
Started
2026-03-19
Last updated
2026-10-22

Condition(s) studied

Malignant Hypertension

Investigational drug(s) / intervention(s)

biobank

biobank: The following samples will be collected : * Serum samples and plasma sample: inclusion visit and follow up visit * Urines samples : inclusion visit and follow up visit * blood DNA: inclusion visit * Blood RNA: inclusion visit and follow up visit

Study summary

The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients included in the HAMA cohort with the following critera : * Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy) * Severe hypertension associated with acute target organ damage due to high blood pressure Exclusion Criteria: * Refusal to participate to the substudy " HAMA bank " * patient on chronic dialysis

Primary outcome measure(s)

  • Decipher the mechanisms responsible for the transition from severe to malignant hypertension — At inclusion and 6 month
    Compare the multiomic signature of patients admitted for malignant hypertension, between MHT acute crisis (admission) and resolution (6 month later). Transcriptomic, proteomic and metabolomic evolution between these 2 time points and focus on genetic background in relevant system, like angiogenic, vasoactif system, complement system and inflammasome will be described.

Trial sites (11)

FacilityCityRegionStatus
CH d'Annecy Annecy France Recruiting
CHU de Bordeaux Bordeaux France Recruiting
CH de Chalon sur Saône Chalon-sur-Saône France Recruiting
Hospices Civils de Lyon Lyon France Not Yet Recruiting
APHP Avicenne Paris France Recruiting
Hôpital Européen Georges Pompidou Paris France Recruiting
Hôpital Paris Saint Joseph Paris France Recruiting
CHU de Strasbourg Strasbourg France Recruiting
CHU de Toulouse Toulouse France Recruiting
CHRU de Tours Tours France Recruiting
CH de Valenciennes Valenciennes France Recruiting

More Centre Hospitalier de PAU trials in France

3-hour Versus 12-hour Double-balloon Catheter for Labor Induction Starting soon
Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia Active, not recruiting
A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort Recruiting

Other trials for the same condition

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06629363 on ClinicalTrials.gov ↗ ← All trials in France